Pediatric acute lymphoblastic leukemia is curable without preventive cranial radiation
June 24, 2009Childhood acute lymphoblastic leukemia (ALL) can be successfully treated using a carefully personalized chemotherapy regimen without cranial radiation, investigators at St. Jude Children's Research Hospital have found. Such radiation of the brain was once a standard ALL treatment to prevent recurrence of the leukemia in the central nervous system (CNS).
Despite radiation's success in treating ALL, it produces side effects that include second cancers, stunted growth, hormone imbalances and cognitive deficits. Optimized use of anticancer drugs, especially those instilled directly into the spinal fluid, have enabled clinicians to reduce radiation use, and only patients at highest risk for relapse have received cranial radiation.
Now, St. Jude researchers have established that radiation can be safely eliminated in all patients with the use of highly effective chemotherapy regimens. The investigators reported their findings in the June 25, 2009, issue of the New England Journal of Medicine.
"Cranial radiation was an invaluable treatment when it was introduced by St. Jude oncologists in the mid-1960s," said Ching-Hon Pui, M.D., chair of the St. Jude Department of Oncology and an American Cancer Society Professor. "It controlled CNS leukemia and boosted the cure rate for ALL from only 4 percent to 50 percent. But radiation's side effects led to the steady reduction of dosages and limited use to the highest-risk patients." According to Pui, the paper's lead author, about 20 percent of the approximately 3,400 cases of childhood ALL diagnosed in the U.S. each year are still treated with radiation. In some developing countries, radiation continues to be used in the majority of children with ALL.
"Over the years, St. Jude investigators have identified many important risk factors for CNS relapse and optimized chemotherapy treatment, leading to improved control of CNS relapse," Pui said. "Our success led us to believe that we could safely eliminate the use of cranial irradiation in all patients, and this study clearly demonstrates that to be true."
The study involved 498 patients treated for ALL at St. Jude and Cook Children's Medical Center in Fort Worth, Texas, between 2000 and 2007. The risk of relapse was determined by measurement of residual leukemia cells (so-called minimal residual disease) that were present after remission induction treatment. The measurement of minimal residual disease was used to modify therapy based on the level of disease detected. This measurement is the most important prognostic indicator, according to Dario Campana, M.D., Ph.D., vice chair for laboratory research in the St. Jude Department of Oncology and a co-author of the paper. "The combined use of immunological and molecular methods allows us to study 100 percent of the patients for levels of minimal residual disease, an unprecedented rate of success," Campana said.
St. Jude investigators applied personalized therapy based on molecular genetics of ALL, pharmacogenetic traits of patients and pharmacodynamic principles. "We prospectively determined the activity of drug-metabolizing enzymes of each patient and adjusted the dosage of chemotherapy accordingly," said Mary Relling, Pharm.D., chair of the St. Jude Department of Pharmaceutical Sciences and senior author of the paper. "Personalized therapy that we use avoids over- or under-treatment to maximize the cure rate while preventing excessive toxicity."
The researchers reported that this therapy produced a projected cure rate of 90 percent for all the patients, which is the best treatment result reported to date. This cure rate serves a benchmark for others in the field. To assess whether cranial irradiation would have made a difference in CNS relapse, they compared the outcomes of 71 patients whose leukemias would have qualified them for irradiation with the outcomes of 56 patients who had received such irradiation in the past. The researchers found that the 71 patients, in fact, had significantly better complete remission than the 56 patients who had been irradiated.
"The bottom line is that not only did we get outstanding treatment responses in these patients, many of whom would have otherwise received irradiation, but they will have a better quality of life because of the absence of its side effects," Pui said.
"In a way, these findings represent coming full circle," Dr. William Evans, St. Jude director and CEO and a co-author of the paper. "St. Jude was the first to introduce cranial radiation as a treatment strategy that advanced the cure of childhood ALL to 50 percent. Now, St. Jude is the first to show that we can successfully eliminate irradiation by optimizing chemotherapy."
Source: St. Jude Children's Research Hospital
-
Study finds more than 100 gene variations linked with response to leukemia treatment
Jan 27, 2009 |
not rated yet |
0
-
Molecular science could further improve leukemia survival
Mar 21, 2008 |
not rated yet |
0
-
Scientists identify genomic causes of a certain type of leukemia relapse
Nov 27, 2008 |
not rated yet |
0
-
Leukemic cells find safe haven in bone marrow
Mar 22, 2007 |
not rated yet |
0
-
Gene abnormality found to predict childhood leukemia relapse
Jan 07, 2009 |
not rated yet |
0
-
Engineers build first sub-10-nm carbon nanotube transistor
Feb 01, 2012 |
4.9 / 5 (32) |
30
-
Something old, something new: Evolution and the structural divergence of duplicate genes
Jan 31, 2012 |
4.6 / 5 (7) |
1
-
The hidden nanoworld of ice crystals: Revealing the dynamic behavior of quasi-liquid layers
Jan 30, 2012 |
5 / 5 (4) |
1
-
Stock market network reveals investor clustering
Jan 27, 2012 |
3.9 / 5 (23) |
8
-
Of microchemistry and molecules: Electronic microfluidic device synthesizes biocompatible probes
Jan 26, 2012 |
5 / 5 (2) |
0
-
Is Everyday Technology Killing Us?
Feb 08, 2012
-
Exercise and weight loss
Feb 08, 2012
-
Why do we have head aches? Our brains can't feel anything.
Feb 07, 2012
-
"The end of diseases" by David Agus, interview from Daily Show with Jon Stewart
Feb 04, 2012
-
Oncolytic adenovirus
Feb 04, 2012
-
Nutrition label stuffs and diets
Feb 02, 2012
- More from Physics Forums - Medical Sciences
More news stories
Starve a virus, feed a cure? Findings show how some cells protect themselves against HIV
A protein that protects some of our immune cells from the most common and virulent form of HIV works by starving the virus of the molecular building blocks that it needs to replicate, according to research published online ...
1 hour ago |
5 / 5 (1) |
0
|
Injured boomers beware: Know when to see doctor
(AP) -- It happened to nurse Jane Byron years after an in-line skating fall, business owner Haralee Weintraub while doing "men's" push-ups, and avid cyclist Gene Wilberg while lifting a heavy box.
3 hours ago |
5 / 5 (1) |
0
FDA-approved drug rapidly clears amyloid from the brain, reverses Alzheimer's symptoms in mice
Neuroscientists at Case Western Reserve University School of Medicine have made a dramatic breakthrough in their efforts to find a cure for Alzheimer's disease. The researchers' findings, published in the journal Science, show t ...
Medicine & Health / Neuroscience
Feb 09, 2012 |
4.9 / 5 (55) |
21
|
Green tea found to reduce disability in the elderly
(Medical Xpress) -- A lot of research has been done over the past several years looking into the health benefits of green tea. As a result, scientists have found that regular consumption of the beverage leads ...
Teen school drop-outs three times as likely to be on benefits in later life
Teen school drop-outs are almost three times as likely to be on benefits in later life as their peers who complete their schooling, indicates research published online in the Journal of Epidemiology and Community Health.
Feb 06, 2012 |
not rated yet |
13
Scientists discover molecular secrets of 2,000-year-old Chinese herbal remedy
For roughly two thousand years, Chinese herbalists have treated Malaria using a root extract, commonly known as Chang Shan, from a type of hydrangea that grows in Tibet and Nepal. More recent studies suggest that halofuginone, ...
New method to examine batteries -- MRI from the inside
There is an ever-increasing need for advanced batteries for portable electronics, such as phones, cameras, and music players, but also to power electric vehicles and to facilitate the distribution and storage of energy derived ...
Lab study raises questions over nano-particle impact
Tests involving chickens have raised questions about the impact on health from engineered nano-particles, the ultra-fine grains commonly used in drugs and processed foods, scientists said on Sunday.
A mitosis mystery solved: How chromosomes align perfectly in a dividing cell
Although the process of mitotic cell division has been studied intensely for more than 50 years, Whitehead Institute researchers have only now solved the mystery of how cells correctly align their chromosomes during symmetric ...
Researchers find extensive RNA editing in human transcriptome
In a new study published online in Nature Biotechnology, researchers from BGI, the world's largest genomics organization, reported the evidence of extensive RNA editing in a human cell line by analysis of RNA-seq data, demons ...
The proteins ensuring genome protection
Researchers from the University of Geneva (UNIGE), Switzerland, have discovered the crucial role of two proteins in developing a cell 'anti-enzyme shield'. This protection system, which operates at the level of molecular ...
Jun 24, 2009
Rank: not rated yet
What they fail to mention here, is that whether using the old or "new" methods, the chance of relapse is 90% when a child udner the age of 5 or so gets ALL. There is then a 90% chance that the relapse will be fatal, no matter what treatment known so far is given.
This just reduces the possibility of other types of cancer being cause due to the radiation, and not the relapse in leukemia itself, which from what i am told by our sons army of doctors, is not effected by these chemo methods (it is a good point to mention however that radiation also did NOT prevent the relapse of leukemia..again, army of doctors)